scholarly journals Technology of obtaining a food additive from citrullus colocynthis and its hypoglycemic activity

2021 ◽  
pp. 68-71
Keyword(s):  
Diabetes Mellitus ◽  
Alloxan Diabetes ◽  
Food Supplement ◽  
Food Additive ◽  
Hypoglycemic Activity ◽  
Citrullus Colocynthis ◽  
Bioactive Substances ◽  
Hypoglycemic Agent ◽  
Pharmacological Studies ◽  
Cucurbitacin E

The aim of the study is to develop a technology for obtaining a food additive for the extract of the pulp of bitter watermelon - Citrullus colocynthis, introduced in Uzbekistan as a hypoglycemic agent. Pharmacological studies have shown the presence of a hypoglycemic effect for aqueous and alcoholic extracts and 2-O-β-glucopyranosyl-cucurbitacin E in rats with alloxan diabetes mellitus. Cucurbitacins were isolated from the extract - cucurbitacin E, 2-O-β-glucopyranosyl-cucurbitacin E and other bioactive substances. The food supplement obtained from bitter watermelon (Citrullus colocynthis (family Cucurbitaceae)) according to the developed technology showed a higher hypoglycemic activity compared to the drug arfazetin.

scholarly journals EFFECT OF THE SALTS OF MESO-OXALIC ACID ON ALLOXAN DIABETES MELLITUS

1951 ◽  
Vol 1 (1) ◽  
pp. 9-21 ◽  
Author(s):  
YOSHITO KOBAYASHI ◽  
SHIGERU OHASHI ◽  
SETSUYA TAKEUCHI
Keyword(s):  
Diabetes Mellitus ◽  
Oxalic Acid ◽  
Alloxan Diabetes

Oligomeric phenylpropanoids having new skeletons and hypoglycemic activity from Magnolia officinalis var. biloba

2021 ◽  
Author(s):  
Kailing Xu ◽  
Chuan Li ◽  
Chuangjun Li ◽  
Jie Ma ◽  
Yingda Zang ◽  
...  
Keyword(s):  
Hypoglycemic Activity ◽  
Pharmacological Studies ◽  
Dual Inhibitors ◽  
Magnolia Officinalis

Three oligomeric phenylpropanoids [(+)/(–)-1 and 2] with new skeletons and a meroterpenoid (3) from Magnolia officinalis var. biloba were identified. Pharmacological studies showed(+)-1 and (–)-1 are PTP1B and α-glucosidase dual inhibitors.

Combined Insulin-Sulfonylurea Treatment of Type II Diabetes

1989 ◽  
Vol 15 (5) ◽  
pp. 450-455 ◽  
Author(s):  
Pauline R. Bingham ◽  
Matthew C. Riddle
Keyword(s):  
Diabetes Mellitus ◽  
Glucose Control ◽  
Type Ii Diabetes ◽  
Multiple Dose ◽  
Health Sciences ◽  
Dependent Diabetes Mellitus ◽  
Type Ii ◽  
Hypoglycemic Agent ◽  
Oregon Health ◽  
Sulfonylurea Drugs

The literature on type II (noninsulin-dependent diabetes mellitus) proposes many forms of treatment. This diversity suggests that there is no single best way to treat this condition. At Oregon Health Sciences University, we have been using the combination of insulin given in the evening and sulfonylurea drugs given during the day as an alternative to multiple-dose insulin regimens when diet or diet and oral hypoglycemic agent therapies do not achieve adequate glucose control. This approach, while effective in our experience, is not widely accepted. This paper reviews the literature on combined insulin and sulfonylurea therapy for treatment of certain stages of type II diabetes, the rationale for use of this therapy, and our experience to date.

Toxicity and developmental effect of cucurbitacin E from Citrullus colocynthis L. (Cucurbitales: Cucurbitaceae) against Spodoptera litura Fab. and a non-target earthworm Eisenia fetida Savigny

2019 ◽  
Vol 27 (19) ◽  
pp. 23390-23401 ◽  
Author(s):  
Athirstam Ponsankar ◽  
Kitherian Sahayaraj ◽  
Sengottayan Senthil-Nathan ◽  
Prabhakaran Vasantha-Srinivasan ◽  
Sengodan Karthi ◽  
...  
Keyword(s):  
Eisenia Fetida ◽  
Spodoptera Litura ◽  
Citrullus Colocynthis ◽  
Developmental Effect ◽  
Cucurbitacin E

INFLUENCE OF THIOCTIC ACID N LABORATORY INDICATORS OF CARBOHYDRATE EXCHANGE IN PATIENTS WITH TYPE II DIABETES MELLITUS

2021 ◽  
pp. 29-35
Author(s):  
Kim V.S. ◽  
Abramova A.N. ◽  
Shur Yu.V. ◽  
Selezneva T.E. ◽  
Tsibizova A.A. ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Carbohydrate Metabolism ◽  
Type Ii Diabetes ◽  
Glycated Hemoglobin ◽  
Type Ii Diabetes Mellitus ◽  
Metformin Hydrochloride ◽  
Thioctic Acid ◽  
Type Ii ◽  
Hypoglycemic Agent ◽  
Normal Body Weight

The work is devoted to assessing the effect of thioctic acid on the main laboratory parameters of carbohydrate metabolism (blood glucose, C-peptide and insulin levels, glycated hemoglobin) in diabetes mellitus against the background of glucose-lowering therapy with metformin hydrochloride. The studies were conducted with the participation of 32 volunteers aged 52 to 63 years, 26 of whom type II diabetes mellitus proceeded with III-degree obesity. At the time of the study, all patients were taking metformin hydrochloride (MH) as a hypoglycemic agent. The experiment was carried out for 3 months. All study participants were divided into groups: the first group - the control group, who took only MG 850 mg once a day for; the second group, patients with normal body weight, who took metformin hydrochloride 850 mg and thioctic acid (TA) 600 mg per day; the third group - obese patients receiving the test compound at the same dosage. After 3 months of treatment, all patients underwent biochemical blood tests for the following parameters: blood glucose, glycated hemoglobin, C-peptide and insulin levels. The results obtained indicate that thioctic acid contributed to a more pronounced decrease in carbohydrate metabolism in comparison with the group of patients receiving only MH as a hypoglycemic agent. It was noted that the normalization of the studied parameters was expressed in the group of patients with normal body weight. Thus, the additional introduction of thioctic acid into the treatment regimen for patients with type II diabetes mellitus contributes to a more effective decrease in carbohydrate metabolism and compensation of the disease in comparison with standard therapy.

Hypoglycemic Activity of Methanol Fraction of Tectona grandis (Linn) Bark in Experimental Rat Models

2021 ◽  
pp. 4247-4252
Author(s):  
Bishwanath Mishra ◽  
Durga M. Kar ◽  
Laxmidhar Maharana ◽  
Sujit Dash ◽  
Ganesh P. Mishra
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Tectona Grandis ◽  
Hypoglycemic Activity ◽  
Oral Glucose ◽  
Alcoholic Extract ◽  
Traditional Use ◽  
Standard Drug ◽  
Single Dose Study ◽  
Dose Study

Diabetes mellitus (DM) is a now a major global health problem and its incidence is increasing day by day in whole world. There are various medicinal plants in India those possess antidiabetic property which are traditionally used in management of diabetes. Tectona grandis Linn. (TG) plant belonging to family Verbenaceae is medicinally reported and claims to cure various diseases in Indian traditional system of medicine (Ayurveda) and also in folklore. The purpose of this present study is to examine the hypoglycemic potential of methanol fractions (50, 100 and 200mg/kg body weight) of Tectona grandis bark (MFTG) from defatted hydro-alcoholic extract in normoglycemic, streptozotocin induced (45mg.kg‒1) diabetic and glucose loaded hyperglycemic rats by single and multiple oral administration in comparison to standard drug Glibenclamide (2.5 mg/kg body weight). Initially acute oral toxicity study of MFTG was carried out in rats to estimate the dose for animal study. The study report showed that the MFTG (200mg/kg) significantly (p<0.05 to p<0.01) reduces blood glucose level both in normoglycemic and diabetic rats induced by Streptozotocin and oral glucose loaded methods till the end of 8 hour and 3hour respectively during the single dose study and from the 15th day to 30th day in multi dose study. Hence the present study reveals that MFTG possess significant hypoglycemic activity which inspires the traditional use of the plant for the treatment of diabetes mellitus.

scholarly journals Structural Elucidation and Immune-Enhancing Effects of Novel Polysaccharide from Grifola frondosa

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Yu-Ri Seo ◽  
Dinesh K. Patel ◽  
Woo-Chul Shin ◽  
Wan-Sup Sim ◽  
Ok-Hwan Lee ◽  
...  
Keyword(s):  
Particle Size ◽  
Cell Activation ◽  
Cell Activity ◽  
Food Additive ◽  
Grifola Frondosa ◽  
Immunological Activity ◽  
Beta Glucan ◽  
Hypoglycemic Agent ◽  
Immune Booster ◽  
Cytokines Secretion

Beta-glucan (β-glucan) is a macromolecule structure where glucose unit has bonded through β-glycosidic bond at 1 and 3 positions. It is well known as a natural immunomodulator without exhibiting any side effects via enhancing immunity. Mushroom contains a large amount of β-glucan and it has anticancerous and antioxidant efficacy. Structure and physical properties of β-glucan are highly influenced by the types of mushroom. In particular, Grifola frondosa has β-1, 3 and β-1, 6 bonds in their structure. It has been noted that β-glucan content also depends upon the size of mushroom particles. The exact content of β-glucan and their immunological activity by a particle size of G. frondosa have yet to be fully elucidated. Herein, β-glucan contents were analyzed according to the particle size of leaf mushroom followed by cell activation and immunoactivity analysis. The highest β-glucan content was observed at a particle size of 20-30 μm (27.65 ± 0.30 w/w). All samples showed ~ 103% cell activation compared to the control and greater cell activity was observed at higher concentration. The significant increase in cytokines secretion was observed in the presence of 20-30 μm particle size of G. frondosa compared to the control. This study suggested that 20-30 μm size is the suitable size of G. frondosa that can be used as a health supplement and food additive to act as an immune booster, hypotensive agent, and hypoglycemic agent.

scholarly journals Electroacupuncture and Rosiglitazone Combined Therapy as a Means of Treating Insulin Resistance and Type 2 Diabetes Mellitus: A Randomized Controlled Trial

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Rong-Tsung Lin ◽  
Huei-Chin Pai ◽  
Yu-Chen Lee ◽  
Chung-Yuh Tzeng ◽  
Chin-Hsien Chang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combined Therapy ◽  
Hypoglycemic Activity ◽  
Model Assessment ◽  
Significant Difference ◽  
Plasma Ffa

Aims.To evaluate the efficacy of rosiglitazone (TZD) and electroacupuncture (EA) combined therapy as a treatment for type 2 diabetes mellitus (T2DM) patients by randomized single-blind placebo controlled clinical trial.Methods.A total of 31 newly diagnostic T2DM patients, who fulfilled the study's eligibility criteria, were recruited. The individuals were randomly assigned into two groups, the control group (TZD,N=15) and the experimental group (TZD + EA,N=16). Changes in their plasma free fatty acid (FFA), glucose, and insulin levels, together with their homeostasis model assessment (HOMA) indices, were statistically compared before and after treatment. Hypoglycemic activity (%) was also compared between these two groups.Results.There was no significant difference in hypoglycemic activity between the TZD and TZD + EA group. The effectiveness of the combined therapy seems to derive from an improvement in insulin resistance and a significant lowering of the secreted insulin rather than the effect of TZD alone on T2DM. The combined treatment had no significant adverse effects. A lower plasma FFA concentration is likely to be the mechanism that causes this effect.Conclusion.This combined therapy seems to suppress endogenous insulin secretion by improving insulin resistance via a mechanism involving a reduction in plasma FFA. This trial is registered with ClinicalTrials.govNCT01577095.

Sign in / Sign up

Export Citation Format

Share Document